/

Empresas

Ma

No verificado

MaaT Pharma

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

44 Comunicados de prensa

Ver todos los comunicados de prensa

06/07/2026

Oncología

Salud

Sanidad

Medicina - Varios

Farmacéutica

Biotecnología

MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract

Fuente

Editor

1.00

0

26/06/2026

Industria

Oncología

Salud

Sanidad

Medicina - Varios

Farmacéutica

Biotecnología

MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease

Fuente

Editor

1.00

0

26/05/2026

Venta al público/Minorista

Eventos

Mercado de valores

Ciencia

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Oncología

MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026

Fuente

Editor

1.00

0

20/05/2026

Oncología

Salud

Sanidad

Medicina - Varios

Ciencia

Farmacéutica

Industria

MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease

Fuente

Editor

1.00

0

01/04/2026

Industria

Eventos

Ciencia

Oncología

Sanidad

Salud

Medicina - Varios

MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal

Fuente

Editor

1.00

0

31/03/2026

Eventos

Mercado de valores

Biotecnología

Farmacéutica

Salud

Oncología

MaaT Pharma Announces 2025 Annual Results and Provides Business Updates

Fuente

Editor

1.00

0

23/03/2026

Eventos

Biotecnología

Sanidad

Salud

Medicina - Varios

Oncología

MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation

Fuente

Editor

1.00

0

09/03/2026

Medicina - Varios

Material médico sanitario

Salud

Farmacéutica

Oncología

MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management

Fuente

Editor

1.00

0

20/01/2026

Ciencia

Medicina - Varios

Sanidad

Salud

Farmacéutica

Oncología

Industria

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis

Fuente

Editor

1.00

0

08/12/2025

Industria

Eventos

Oncología

Salud

Ciencia

Sanidad

Medicina - Varios

MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0